<?xml version="1.0" encoding="UTF-8"?>
<modsCollection xmlns="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd">
  <mods>
    <titleInfo>
      <title>Immune response to #Plasmodium falciparum$ liver stage antigen-1 : geographical variations within Central Africa and their relationship with protection from clinical malaria</title>
    </titleInfo>
    <name type="personnal">
      <namePart type="family">Migot Nabias</namePart>
      <namePart type="given">F.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Deloron</namePart>
      <namePart type="given">Philippe</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Ringwald</namePart>
      <namePart type="given">Pascal</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Dubois</namePart>
      <namePart type="given">B.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Mayombo</namePart>
      <namePart type="given">J.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Minh</namePart>
      <namePart type="given">T.N.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Fievet</namePart>
      <namePart type="given">Nadine</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Millet</namePart>
      <namePart type="given">P.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <typeOfResource>text</typeOfResource>
    <genre authority="local">journalArticle</genre>
    <language>
      <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
    </language>
    <physicalDescription>
      <internetMediaType>text/pdf</internetMediaType>
      <digitalOrigin>reformatted digital</digitalOrigin>
      <reformattingQuality>access</reformattingQuality>
    </physicalDescription>
    <abstract>Two populations of schoolchildren from Gabon and Cameroon were tested in 1995 for their immunological reactivity to synthetic peptides (LSA-Rep, LSA-J and LSA-CTL) from Plasmodium falciparum liver stage antigen-1 (LSA-1). The prevalence and levels of both cellular (lymphocyte proliferation, tumour necrosis factor alpha (TNF-alpha), interferon gamma (IFN-gamma), and interleukin-10 (IL-10)) and humoral (immunoglobulin G) responses were determined. Protection from clinical malaria, determined after a prospective 1 year study in both sites, was associated with elevated proliferative responses to LSA-Rep and LSA-CTL in the Gabonese children, as well as with higher antibody levels to both schizont extract and LSA-Rep. The prevalence of peptide-stimulated TNF-alpha secretion was higher in the Cameroonian group, but higher levels of antibodies to LSA-Rep and LSA-J were found in the Gabonese children. The immunological differences observed between children in the 2 study sites are discussed in the context of both epidemiological and individual host factors. (Résumé d'auteur)</abstract>
    <targetAudience authority="marctarget">specialized</targetAudience>
    <subject authority="local">
      <topic>PALUDISME</topic>
      <topic>IMMUNOLOGIE</topic>
      <topic>ENFANT D'AGE SCOLAIRE</topic>
      <topic>VACCINATION</topic>
      <topic>ANTIGENE</topic>
      <topic>TEST ELISA</topic>
      <topic>ANTICORPS</topic>
      <topic>ANALYSE STATISTIQUE</topic>
      <topic>ETUDE REGIONALE</topic>
      <topic>ETUDE COMPARATIVE</topic>
    </subject>
    <subject>
      <topic>LSA1.LIVER STAGE ANTIGEN 1</topic>
      <topic>TNF ALPHA.TUMOR NECROSIS FACTOR ALPHA</topic>
      <topic>IFN GAMMA.INTERFERON GAMMA</topic>
      <topic>IL10.INTERLEUKIN 10</topic>
      <topic>LPA.LYMPHOCYTE PROLIFERATIVE ASSAY</topic>
      <topic>CYTOKINE</topic>
      <topic>CELLULE T</topic>
    </subject>
    <subject authority="local">
      <geographic>CAMEROUN</geographic>
      <geographic>GABON</geographic>
    </subject>
    <classification authority="local">052ANOPAL04</classification>
    <relatedItem type="host">
      <titleInfo>
        <title>Transactions of the Royal Society of Tropical Medicine and Hygiene</title>
      </titleInfo>
      <part>
        <detail type="volume">
          <number>94</number>
        </detail>
        <detail type="volume">
          <number>5</number>
        </detail>
        <extent unit="pages">
          <list> 557-562</list>
        </extent>
      </part>
      <originInfo>
        <dateIssued>2000</dateIssued>
      </originInfo>
      <identifier type="issn">0035-9203</identifier>
    </relatedItem>
    <identifier type="uri">https://www.documentation.ird.fr/hor/fdi:010024068</identifier>
    <identifier type="doi">10.1016/S0035-9203(00)90086-5</identifier>
    <identifier type="issn">0035-9203</identifier>
    <location>
      <shelfLocator>[F B010024068]</shelfLocator>
      <url usage="primary display" access="object in context">https://www.documentation.ird.fr/hor/fdi:010024068</url>
      <url access="row object">https://horizon.documentation.ird.fr/exl-doc/pleins_textes/pleins_textes_7/b_fdi_57-58/010024068.pdf</url>
    </location>
    <recordInfo>
      <recordContentSource>IRD - Base Horizon / Pleins textes</recordContentSource>
      <recordCreationDate encoding="w3cdtf">2001-02-06</recordCreationDate>
      <recordChangeDate encoding="w3cdtf">2021-05-20</recordChangeDate>
      <recordIdentifier>fdi:010024068</recordIdentifier>
      <languageOfCataloging>
        <languageTerm authority="iso639-2b">fre</languageTerm>
      </languageOfCataloging>
    </recordInfo>
  </mods>
</modsCollection>
